Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is currently ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...

Occupational studies stretching back decades have found an increased risk of bladder cancer among hairdressers.

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

A popular Emmerdale actor has issued a warning to fans of the ITV show after he underwent surgery to have cancerous cells removed ...

A popular Emmerdale actor has issued a warning to fans of the ITV show after he underwent surgery to have cancerous cells removed.

Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results ...

Survivors of blood or marrow transplants (BMT) face a significantly higher risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and ...